BRISBANE, Calif., June 07, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on June 4, 2024, the Compensation Committee of Vera’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 31,250 shares of Class A common stock and restricted stock units (RSUs) for 14,500 shares of Class A common stock to five new employees under Vera’s 2024 Inducement Plan (the Inducement Plan). The Compensation Committee approved the aw
BRISBANE, Calif., June 07, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will participate in the Goldman Sachs 45th Annual Global Healthcare Conference, taking place June 10 – 13, 2024 at the Loews Miami Beach Hotel, Miami Beach, FL. Presentation Details: Date: Wednes
BRISBANE, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to atacicept for the treatment of IgAN. The designation reflects the FDA’s determination that, based on an assessment of data from the Ph